Jun
9
2020
On demand

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

With the increasing availability of anti-cancer drugs, the critical role of immune cells in cancer therapy has been validated, and adoptive cell therapies are more frequently a treatment of choice.

A number of challenges remain in the manufacture of these therapies, especially as we look to move to commercial-scale production. These challenges have caused industry participants to express concerns that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these living therapies.

Upscaling and streamline manufacturing processes are key to ensure future successes in the clinic. In this webinar, we will introduce Miltenyi Biotec’s solutions and discuss the generation of gene-modified CAR-T and CAR NK cells in a standardized and fully automated fashion with academic and industry end user panellists.

Attendees learn:

  • How to enable easy translation and upscaling of CAR-T and NK cell manufacturing
  • How to harness closed system automation for manufacturing of CAR-T and NK cells
  • Which solutions are available for IPC/QC of cellular products (CAR-T/NK) and beyond (potency assays, killing assays, immuno-monitoring)
  • What the cell factory of the future will look like

Martha Elia Luevano Salinas

Martha Elia Luevano Salinas, PhD

Global Product Manager, Group Leader, Immunology Engineered Cells

Martha Luevano is responsible for the clinical Engineered cells portfolio including CAR-T and CAR NK cells at Miltenyi Biotec. During the past 5 years, she has been working together with R&D and the Clinical Development team in order to advance the development of tools to enable CAR-T and CAR NK cell immunotherapy. Prior to joining Miltenyi Biotec, Martha did her postdoctoral research in stem cells (Miltenyi Biotec-Marie Curie fellowship) and her PhD in the Anthony Nolan (University College London) finding solutions to expand NK cells for therapeutic purposes. Her combined experience in molecular and cellular research has made her the recipient of international grants and fellowships.

Xiuyan Wang, PhD

Xiuyan Wang, PhD

Associate Director, Michael G. Harris Cell Therapy and Cell Engineering Facility; Associate Lab Member in the Department of Molecular Pharmacology

Dr. Wang was trained by Dr. Adolfo García-Sastre and received her PhD in Biomedical Sciences from the Mount Sinai School of Medicine in New York. She joined Dr. Peter Cresswell’s laboratory in the Department of Immunology at Yale University as a Howard Hughes Medical Institute fellow, and later as a Cancer Research Institute postdoctoral associate. Dr. Wang joined Memorial Sloan Kettering Cancer Center in 2007, and is currently the Associate Director of the Michael G Harris Cell Therapy and Cell Engineering Facility, and an Associate Lab Member in the Department of Molecular Pharmacology. Dr. Wang is in charge of the R&D, process development and manufacturing. She has overseen the successful manufacturing of all the CAR- T cell products used in 13 phase I/II clinical trials, over 20 batches of cGMP grade viral vectors, as well as tech transfers to multiple industrial partners. She served in the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT). She is currently a member for the National Heart, Lung and Blood Institute (NHLBI) independent external expert panel and a committee member for the Alliance of Regenerate Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

Dr Stephan Fricke

Head of GMP Process Development, Fraunhofer Institute for Cell Therapy and Immunology

Stephan Fricke began his medical studies at the University of Leipzig in 1999, which he successfully completed in 2005. He then began his specialist training and completed his doctorate at the University of Leipzig in 2007. Since 2006 he has been working as a research group leader at Fraunhofer IZI in Leipzig in addition to his clinical activities. Here he leads several research projects dealing with increasing the safety and efficiency of stem cell transplantation for leukemia and lymphoma, develops antibody-based therapies and CAR-ATMP strategies for stem cell transplantation with a focus on clinical applicability. During this time, he completed his training as a specialist in internal medicine and haematology and oncology, acquired the specialist immunologist from DGfI and completed his habilitation. Since 2019 he is also head of the GMP process development unit at Fraunhofer IZI. This department realizes the transfer of manufacturing processes from the laboratory to a clinical scale. With the aim of obtaining official manufacturing authorizations for the production of clinical test samples, GMP-compliant processes are newly developed or existing processes are adapted and optimized. The focus is on cell- and gene-based drugs (Advanced Therapy Medicinal Products). These include antigen-specific T cells, CAR T cells and CAR NK cells. The development of GMP-compliant manufacturing protocols is closely accompanied by the definition of corresponding quality controls. In the development unit, process adaptations can be tested and optimized flexibly and cost-effectively.

Sarah Dluczek, MsC

Sarah Dluczek, MsC

Technical Leader, GMP Unit, Fraunhofer Institute for Cell Therapy and Immunology

Sarah Dluczek is a technical manager in the GMP development unit in the field of ATMPs (Advanced Therapy Medicinal Products) at Fraunhofer Institute for Cell Therapy and Immunology, Leipzig. In 2015, she completed her bachelor’s degree in biology and her master’s degree in pharmaceutical biotechnology in 2018. She joined the Immune Tolerance Unit lead by PD Dr. Stephan Fricke in 2017. She is now responsible for the development and optimization of GMP manufacturing processes for ATMPs.

Dr Kate Fynes

Dr Kate Fynes

Investigator, Process Development – Cell and Gene Therapy Platform, GlaxoSmithKline

Kate graduated from University College London with a PhD in Stem Cell Bioprocessing before undertaking a postdoctoral position at the Institute of Ophthalmology, UCL. Here, as part of The London Project team, she developed and transferred an embryonic stem cell-derived ATMP from research through to GMP clinical manufacture as part of a FTIH clinical trial. She joined GSK’s CGT Product Development team in 2017, where she now works to deliver the CMC aspects of various T cell assets from early phase through to launch, and the development of innovative technologies to enable step-change improvements to CGT manufacture. Kate specializes in cell process development, seeking to optimize the manufacture of CGT-based treatments, using increased automation and leading-edge processing technology.

Dr Prof. Dr. Ulrike Köhl

Dr Prof. Dr. Ulrike Köhl

Director, Fraunhofer Institute for Cell Therapy and Immunology Leipzig

Prof. Ulrike Köhl, PhD, M.D. is an immunologist and a Qualified Person and since December 2017 full professor for immune oncology at the University of Leipzig as well as the head of the Fraunhofer Institute for Cellular Therapeutics and Immunology in Leipzig, Germany. From 2012 – 2017 she was a full professor and the director of the Institute of Cellular Therapeutics at the Hannover Medical School, Germany. Currently she is sharing a position between Leipzig and Hannover in order to set up a network for advanced cellular therapeutics. She studied both, biology and medicine, received her PhD in 1995 and continued her scientific work at the MD Anderson Cancer Centre in Houston, USA. In 1999 she became the head of the laboratory of stem cell transplantation and immunotherapy in the Paediatric Haematology and Oncology at the University Hospital, Frankfurt, Germany.

SPEAKERS

Martha Luevano
Global Product Manager at Miltenyi Biotec
Xiuyan Wang
Assistant Director, Michael G. Harris Cell Therapy & Cell Engineering Facility at Memorial Sloan-Kettering Cancer Center
Stephan Fricke
Head of GMP Process Development at Fraunhofer Institute for Cell Therapy & Immunology IZI
Sarah Dluczek
Technical Leader, GMP Unit at Fraunhofer Institute for Cell Therapy & Immunology IZI
Kate Fynes
Process Development Investigator, Cell & Gene Therapy CMC at GlaxoSmithKline
Ulrike Koehl
Director & Head, Institute of Cell Therapeutics & GMP Development Unit at Hannover Medical School

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
8
Hrs
5
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
8
Hrs
5
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
9
Days
8
Hrs
5
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
7
Days
8
Hrs
5
Min
Register

Strategic partnering to enable cell therapy commercialization

J Smith
X de Mollerat du Jeu
Jenessa Smith
Jenessa Smith
Associate Director of Process Development at ArsenalBio
Xavier de Mollerat du Jeu
Xavier de Mollerat du Jeu
Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific
12 May 2022
Watch now